Regulatory Press Releases
PILA PHARMA PROACTIVELY MOVES FORWARD WITH PP-CT03 CLINICAL TRIAL APPLICATION FOR STUDY IN PEOPLE LIVING WITH OBESITY AND DIABETES
Malmö, 30 April 2025 PILA PHARMA AB (publ) (FN STO: PILA) today informs the continuation of preparations for the clinical trial application for PP-CT03, a pivotal and pioneering 12-week Phase 2a study evaluating XEN-D0501, a TRPV1 antagonist, in people living with diabetes and obesity.PP-CT03 is designed to assess the safety and tolerability of increasing doses of XEN-D0501 vs placebo, as…
KALLELSE TILL ÅRSSTÄMMA I PILA PHARMA AB
Malmö i mars 2025 Aktieägarna i PILA PHARMA AB (publ), org.nr 556966-4831, ("PILA PHARMA" eller "Bolaget") kallas härmed till årsstämma tisdag den 29 april 2025, kl. 15.00 i MAQS Advokatbyrås lokaler på Gibraltargatan 7 i Malmö. Registrering till stämman börjar kl. 14.30. Anmälan Aktieägare, som önskar delta vid årsstämman, ska (i) dels vara införd i den av Euroclear Sweden AB förda…
PILA PHARMA PUBLISHES THE ANNUAL REPORT 2024
Malmö, 27 March 2025 PILA PHARMA AB (publ) (FN STO: PILA) announces that the annual report (in Swedish) is now available on the Company´s homepage, https://pilapharma.com/investors/finansiell-information/, and as an attachment to this press release. ”This was a year with many changes, alterations, new shareholders and progress has come and gone. We conducted our management ‘re-calibration’ in April 2024, when our founder,…
PILA PHARMA PUBLISHES YEAR-END REPORT (1 JANUARY – 31 DECEMBER 2024)
Malmö, February 27, 2025 PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company's year-end report for the period January - December 2024. The report can be found on the Company's website: https://pilapharma.com/investors/finansiell-information/ SUMMARY OF YEAR-END REPORT SECOND HALF YEAR (1 JULY- 31 DECEMBER 2024) Operating income amounted to TSEK 107 (366) The operating result (EBIT) totalled to TSEK -…
PILA PHARMA ANNOUNCES PRECLINICAL PROOF-OF-CONCEPT ACHIEVED IN CARDIOVASCULAR DISEASE STUDY
Malmö, 18 December 2024 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the completion of the study of the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden (the "Research Group"). The preliminary results showed that PILA PHARMA's lead candidate, the TRPV1 antagonist, XEN-D0501, significantly reduced Abdominal Aorta Aneurysm growth in mice, establishing preclinical proof-of-concept. The hypothesis is…